Eli Lilly presented early clinical results for brenipatide, its once-weekly dual GIP/GLP-1 receptor agonist, showing dose-selection support across substance use, psychiatric, and immunologic disorders. At Psych Congress 2026, Lilly shared findings from its Phase I J2S-MC-GZMD trial (NCT06606106), which evaluated safety, pharmacokinetics, and pharmacodynamics in healthy volunteers as well as overweight and obese participants. Lilly reported a mean half-life range of about 9.08 to 12.5 days, with longer exposure observed at the highest dose tested (4.5 mg). The company said the pharmacokinetic profile supports durability of exposure beyond weekly dosing, aligning with its neuroscience development approach. Lilly also outlined Phase III trial designs for major depressive disorder (MDD) and alcohol use disorder (AUD), aiming to translate CNS-targeted biology into registrational evidence for debilitating psychiatric conditions.